This Content Component encountered an error
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, Taylor J, Watkins H. Eur Heart J. 2010 Apr;31(8):926-35.


Recent advances in the understanding of the molecular genetics of cardiomyopathies present new challenges for clinicians that manage patients with these heart muscle diseases. Cardiologists in particular have to learn how to integrate this new knowledge into diagnostic strategies in order to improve the management of families with inherited cardiomyopathies. However the translational of this technology to routine practice is low. One reason for is probably the lack of data and uncertainties about the economic efficiency of such a strategy.

Wordsworth et al. recently published a cost-effectiveness study in Hypertrophic cardiomyopathy (HCM). HCM is the most common monogenic cardiac disorder and most frequent cause of sudden cardiac death (SCD) in young people and trained competitive athletes. Disease prevalence amongst adults is around 0.2% (1:500) and in recent studies the annual SCD rate from HCM is about 1% on average. HCM is caused by mutations in at least ten sarcomeric protein encoding genes and the inheritance is autosomal dominant, with the child of an affected parent having a 50% chance of inheriting the disease causing allele. The HCM phenotype is dynamic and the onset of cardiac expression (left ventricular hypertrophy diagnosed by echocardiography or ECG) may be delayed until adulthood, and sometimes until 40 to 60 years of age, a phenomenon known as age-related penetrance. Clinically, this presents a problem when assessing families with HCM, and the currently recommended follow-up strategy of relatives involves repeat evaluations every 1 to 5 years (according to age) with echocardiography and ECG.

Myocardial Disease

Summary of the paper

The authors explored the cost-effectiveness of alternative methods of screening family members for HCM. They used an economic decision model comparing cascade screening by genetics, as opposed to clinical methods, for identifying individuals at risk of sudden death due to HCM. The model was built to estimate the lifetime resource costs and health outcomes (life years gained) of alternative strategies for assessing first degree asymptomatic family members of an individual diagnosed with HCM (proband). According to detailed information from the literature, various information and simulations were entered into the model including the familial structure (1 to 3 children, the youngest aged 18 years old), the yield of genetic testing (63% in the proband, then 50% in each child), the sensitivity and specificity of screening tests (such as those of ECG and echocardiography according to age-groups), and the natural history of the disease (such as the prevalence of sudden death major risk factors and related mortality rates). Costs of alternative screening strategies were evaluated according to UK estimation, including the cost of molecular testing (552 euros for the proband, 225 euros for a relative), of regular cardiac examination (ECG and echocardiography every 5 years), of associated consultations (cardiologist, geneticist sessions) as well as cost of ICD implantation (16910 euros), ICD replacement and follow-up.

The incremental cost per life year saved was 14397 euros for the cascade genetic compared with the cascade clinical approach, which is well bellow the acceptable threshold of 35000 euros per life saved (according to NICE decision making guidance, National Institute of Health and Clinical Excellence, UK). Genetic diagnostic strategies were more likely to be cost-effective than clinical tests alone. The costs for cascade molecular genetic testing were slightly higher than clinical testing in the short run, but this was largely because the genetic approach is more effective and identifies more individuals at risk.

Comments and discussion

The authors concluded that the use of molecular genetic information in the diagnosis and management of HCM is a cost-effective approach to the primary prevention of SCD in these patients. One explanation is that genetic strategy is able to discharge more individuals (individuals who do not carry the mutation) when compared to the clinical investigation.
This study represents a turning point as it is the first economic evaluation of the impact of genetic testing in hereditary cardiac diseases and the conclusion is clearly in favour of the use of genetic testing in familial screening.
Potential limitations of this economic decision model are related to the precise scenarios that were addressed but the authors carefully examined the detailed issues related to the strategies they evaluated. The price of genetic testing used for the proband was quite cheap and may have overestimated the real benefit of the genetic strategy, although such low price will be diffused very soon in many laboratories thanks to the coming next generation sequencing (NGS) that will revolutionize genetic practice. On the other hands, some points may have underestimated the benefit of genetic strategy as only first degree relatives were taken into account whereas other relatives may benefit from the cascade strategy thus amplifying the cost savings.


The results of this paper fully support the increasing use of genetic testing and genetic counselling in families with a cardiomyopathy. They also suggest a need for better reimbursement of genetic testing by national health care systems.


 1. Maron BJ, et al. ACC/ESC Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy.  Eur Heart J 2003;24:1965–1991.
2. Elliott P & McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363:1881–1891.
3. Maron BJ. Hypertrophic Cardiomyopathy: a systematic review. J Am Med Assoc 2002; 287:1308–1320.
4. Richard P et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2171–2174.
5. NICE. Social value judgments: principles for the development of NICE guidance. 8 December 2005.
6. You JJ et al. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. 2007 Nov;154(5):899-907.
7. Briggs A, Sculpher M, Claxton K. Decision Modeling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.

Notes to editor

Presented by Philippe Charron, Centre national de référence pour les maladies cardiaques héréditaires, Hôpital Pitié-Salpêtrière, Université Paris 6, Paris, France.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

Contact us

ESC Working Group on Myocardial & Pericardial Diseases

European Society of Cardiology

European Heart House
Les Templiers
2035 Route des Colles
CS 80179 Biot

06903, Sophia Antipolis, FR

Tel: +